Lieber Prize for Outstanding Achievement in Schizophrenia Research

Lieber Prize for Outstanding Achievement in Schizophrenia Research

Established in 1987 by Constance E. Lieber, Foundation President Emerita, and her husband, Stephen A. Lieber, currently Chairman of the Foundation’s Board of Directors, to bring public recognition to the outstanding discoveries being made in schizophrenia research. This prize carries an award of $50,000.

Nominations are now open for the 2017 Lieber Prize. Please submit your nominations by Wednesday, May 24, 2017
​Nomination Instructions

2017 Prizewinners

Michael F. Green, Ph.D.

Professor, Semel Institute for Neuroscience and Human Behavior

Dr. Green’s clinical research laboratory explores the relationship between cognitive and social cognitive impairments in schizophrenia and activities of daily living. His team also explores the neural mechanisms of cognitive and social cognitive dysfunction in schizophrenia and bipolar disorder. Dr. Green is a leading researcher in the evaluation of social cognitive retraining and novel pharmacological interventions to improve cognitive impairments. His laboratory also studies the determinants of community integration for homeless veterans, many of whom have psychotic disorders. His identification of the importance of cognition in schizophrenia launched the national Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) effort, and stimulated novel and innovative treatments for cognitive dysfunction.

Prizewinner Video:

Stephen R. Marder, M.D.

Professor, Psychiatry and Biobehavioral Sciences

Director, Section on Psychosis

During his career, Dr. Marder has focused on pharmacological and non-pharmacological approaches to improving the outcomes of serious mental illnesses, particularly schizophrenia. His clinical intervention research began with studies that evaluated strategies for reducing adverse side effects of antipsychotic medications, and studies that evaluated the interactions of psychosocial interventions and pharmacological approaches to improving the outcome of serious mental illnesses. Together with Dr. Green, his fellow Lieber Prize recipient, he led the NIMH-MATRICS initiative, which addressed key issues in the development of medications for improving cognition in schizophrenia.